EMA committee recommends approval of TG Therapeutics Briumvi to treat relapsing forms of multiple sclerosis in adults

EMA committee recommends approval of TG Therapeutics Briumvi to treat relapsing forms of multiple sclerosis in adults

By, Admin 4 March 2023

TG Therapeutics, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Briumvi (ublituximab-xiiy) for the treatment of adult patients relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. Briumvi is the first and only anti-CD20 monoclonal antibody approved in the US for adult patients with RMS that can be administered in a one-hour infusion following the starting dose. Briumvi was granted approval by the US Food and Drug Administration on December 28, 2022, for the treatment of RMS in adults. Michael S. Weiss, the company's chairman and chief executive officer, stated, "The positive recommendation to approve Briumvi by the CHMP takes us one step closer to delivering Briumvi to patients and healthcare providers in Europe. Following today

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!